Author:
Barlesi Fabrice,Garon Edward B.,Kim Dong-Wan,Felip Enriqueta,Han Ji-Youn,Kim Joo-Hang,Ahn Myung-Ju,Fidler Mary Jo,Gubens Matthew A.,de Castro Gilberto,Surmont Veerle,Li Qiao,Deitz Anne C.,Lubiniecki Gregory M.,Herbst Roy S.
Funder
Bristol-Myers Squibb
Boehringer Ingelheim
Lilly
Merck
Genentech
Novartis
Pfizer
Celgene
Merck Sharp & Dohme
AbbVie
ARIAD
Roche
Lilly and Company
Pharmaceuticals
Eli Lilly and Company
EMD Serono
Merck and Company
Sanofi
Seattle Genetics
Shire plc
Spectrum Pharmaceuticals
Merck Sharp & Dohme Corp.
Merck & Co., Inc.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference34 articles.
1. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000
2. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non–small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial;Garon;Lancet,2014
3. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008
4. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016
5. KEYTRUDA (pembrolizumab). Full Prescribing Information, Merck Sharpe & Dohme, Corp,2018